CLINICAL TRIALS PROFILE FOR ISOPTIN
✉ Email this page to a colleague
All Clinical Trials for ISOPTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00133692 ↗ | INVEST: INternational VErapamil SR Trandolapril STudy | Completed | Abbott | Phase 4 | 1997-09-01 | Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA). |
| NCT00133692 ↗ | INVEST: INternational VErapamil SR Trandolapril STudy | Completed | University of Florida | Phase 4 | 1997-09-01 | Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA). |
| NCT00168519 ↗ | Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes | Completed | Diabetes Australia | N/A | 2002-10-01 | The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise. |
| NCT00168519 ↗ | Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes | Completed | Hoffmann-La Roche | N/A | 2002-10-01 | The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ISOPTIN
Condition Name
Clinical Trial Locations for ISOPTIN
Trials by Country
Clinical Trial Progress for ISOPTIN
Clinical Trial Phase
Clinical Trial Sponsors for ISOPTIN
Sponsor Name
